💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Poly Medicure Limited is an India-based medical device manufacturer and exporter, with its products sold in over 125 countries. The Company is primarily in the business of manufacturing and selling medical devices. With a portfolio of over 200 medical devices and more than…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, fast-growing business, trading cheap versus its own history.
Poly Medicure is scored on the pharma / healthcare framework. It keeps a healthy 16.1% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.77×) — worth a closer look. Free cash flow is worth about 0.1% of its market value.
Over the last 3 years revenue compounded at 20%/yr and profit at 21%/yr. Book value itself has compounded 36%/yr — the hallmark of a genuine compounder. Return on equity is a modest 9.8%. In the latest quarter profit grew 31% versus the prior quarter.
At 51× earnings, the stock sits at the 15th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price already implies ~22%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of B, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 51.52 | 36.85 | worse |
| P/B | 4.99 | 2.77 | worse |
| EV/EBITDA | 27.98 | 16.77 | worse |
| ROE | 9.75 | 8.8 | better |
| ROCE | 12.18 | 11.83 | better |
| ROA | 7.61 | — | — |
| Quick Ratio | 2.62 | 3.03 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 20% CAGR over 3 years — high-growth territory. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak.
Operating margins have been stable around 21% — no major structural shift.
ROE at 10% — modest; the capital isn't working hard.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (21% vs 19%) — share dilution is eroding per-share value. 19% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 11% above earlier ones.
Profit jumped 31% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (19% → 15%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 62.4% — majority control intact. FIIs trimmed 4.1pp — foreign money is rotating out.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.